Two new drugs, the first capable of slowing down the debilitating progression of Alzheimer's disease, have become embroiled ...

Company is investing $2.8bn in two Irish plants to produce its in-demand weight loss drugs and a new Alzheimer’s therapy ...

With a new investment in its two manufacturing sites in Ireland, Eli Lilly continues implementing the largest expansion ...

Eli Lilly and Company’s LLY stock has risen 21.1% in six months ... In July, Lilly won a long-awaited FDA approval for ...

In the United States and some countries other than Europe, Lilly owns exclusive development and commercialization rights to ...

Most trillion-dollar companies today are in the technology sector, but one particular healthcare stock is knocking on the ...

Eli Lilly and Company LLY announced that the FDA ... In July, Lilly won a long-awaited FDA approval for Kisunla (donanemab) for treating early symptomatic Alzheimer's disease.

The FDA’s approval of Kisunla demonstrates a positive change in Alzheimer disease management. Offering illness pathology therapy and the option of treatment conclusion after reaching therapeutic goals ...

By Pam Belluck The modest benefits of the treatment, donanemab, made by Eli Lilly, outweigh the risks, the panel concluded unanimously. By Gina Kolata and Pam Belluck The F.D.A. gave full approval ...

The U.S. Food and Drug Administration (FDA) approved Kisunla™ (donanemab-azbt, 350 mg/20 mL once-monthly injection for IV infusion), Eli Lilly and Company's (NYSE: LLY) Alzheimer's treatment for ...